However, KRAS mutations co-occur commonly with mutations in tumor suppressor genes including TP53, STK11 and KEAP1/NFE2L2, and a growing body of evidence suggests that these co-occurring mutations are associated with unique tumor characteristics and biological behaviors [23]. Here, NFE2L2 is linked to neoplasm.